Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01762475 · ClinicalTrials.gov registry record · Phase 2
Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.
A Phase 2 study, sponsored by Uniformed Services University of the Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01762475: Completed Phase 2 study, sponsored by Uniformed Services University of the Health Sciences.
NCT01762475 is a Phase 2 study that has completed, run by Uniformed Services University of the Health Sciences. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01762475, a Phase 2 study, has completed, sponsored by Uniformed Services University of the Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether sildenafil (Viagra®) is effective in improving cerebral blood flow and cerebrovascular reactivity inpatients who have persistent symptoms at least 6 months after a traumatic brain injury (TBI).
Primary Outcome
Single dose treatment with sildenafil (50 mg orally) is effective in increasing the global BOLD response to hypercapnia in symptomatic patients in the chronic stage after TBI.
Interventions
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT01762475 record still lists
NCT01762475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 1 intervention - of which Sildenafil is the first listed.
NCT01762475 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01762475 about?
NCT01762475 is a clinical study titled "Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.". The purpose of this study is to determine whether sildenafil (Viagra®) is effective in improving cerebral blood flow and cerebrovascular reactivity inpatients who have persistent symptoms at least 6 months after a traumatic brain injury (TBI).
What is the current status of trial NCT01762475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2013-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01762475?
The interventions under investigation include: Sildenafil (DRUG).
Who is sponsoring clinical trial NCT01762475?
This trial is sponsored by Uniformed Services University of the Health Sciences, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01762475's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia